CN1072723A - 三精氨酸胰岛素 - Google Patents

三精氨酸胰岛素 Download PDF

Info

Publication number: CN1072723A
Authority: CN; China
Prior art keywords: tri; arginine; insulin; human proinsulin; proinsulin
Prior art date: 1991-11-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN92113309A

Other languages

English (en)

Chinese (zh)

Inventor

J·A·霍夫曼

P·K·兰布伊

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-26

Filing date

1992-11-25

Publication date

1993-06-02

1992-11-25 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

1993-06-02 Publication of CN1072723A publication Critical patent/CN1072723A/zh

Status Pending legal-status Critical Current

Links

102000004877 Insulin Human genes 0.000 title claims abstract description 107
108090001061 Insulin Proteins 0.000 title claims abstract description 107
239000004475 Arginine Substances 0.000 title claims abstract description 85
239000004026 insulin derivative Substances 0.000 title claims description 82
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 40
238000002360 preparation method Methods 0.000 claims abstract description 23
229940125396 insulin Drugs 0.000 claims abstract description 16
150000001875 compounds Chemical class 0.000 claims abstract description 9
108010076181 Proinsulin Proteins 0.000 claims description 76
238000000034 method Methods 0.000 claims description 37
108010059378 Endopeptidases Proteins 0.000 claims description 8
102000005593 Endopeptidases Human genes 0.000 claims description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
108090000631 Trypsin Proteins 0.000 claims description 6
102000004142 Trypsin Human genes 0.000 claims description 6
239000012588 trypsin Substances 0.000 claims description 6
102000003670 Carboxypeptidase B Human genes 0.000 claims description 5
108090000087 Carboxypeptidase B Proteins 0.000 claims description 5
239000004472 Lysine Substances 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000002955 isolation Methods 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
150000001413 amino acids Chemical group 0.000 abstract description 36
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract description 17
238000006467 substitution reaction Methods 0.000 abstract description 11
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract description 9
210000004899 c-terminal region Anatomy 0.000 abstract description 7
239000000126 substance Substances 0.000 abstract description 6
101000976075 Homo sapiens Insulin Proteins 0.000 abstract description 5
230000002218 hypoglycaemic effect Effects 0.000 abstract description 5
239000000203 mixture Substances 0.000 abstract description 4
230000007774 longterm Effects 0.000 abstract description 2
238000006911 enzymatic reaction Methods 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 description 32
229940024606 amino acid Drugs 0.000 description 32
239000000243 solution Substances 0.000 description 23
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 16
235000018102 proteins Nutrition 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 12
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 11
150000003839 salts Chemical class 0.000 description 11
239000012530 fluid Substances 0.000 description 10
238000013016 damping Methods 0.000 description 9
239000000686 essence Substances 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 9
DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
229930182817 methionine Natural products 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
-1 J. etc. Proteins 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 5
229950004152 insulin human Drugs 0.000 description 5
239000000047 product Substances 0.000 description 5
238000010254 subcutaneous injection Methods 0.000 description 5
239000007929 subcutaneous injection Substances 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
102000013266 Human Regular Insulin Human genes 0.000 description 4
108010090613 Human Regular Insulin Proteins 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229940103471 humulin Drugs 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
239000000758 substrate Substances 0.000 description 4
OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 3
HAVKMRGWNXMCDR-STQMWFEESA-N Arg-Gly-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HAVKMRGWNXMCDR-STQMWFEESA-N 0.000 description 3
108010075254 C-Peptide Proteins 0.000 description 3
GCDLPNRHPWBKJJ-WDSKDSINSA-N Cys-Gly-Glu Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O GCDLPNRHPWBKJJ-WDSKDSINSA-N 0.000 description 3
XTHUKRLJRUVVBF-WHFBIAKZSA-N Cys-Gly-Ser Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O XTHUKRLJRUVVBF-WHFBIAKZSA-N 0.000 description 3
IWUFOVSLWADEJC-AVGNSLFASA-N Gln-His-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O IWUFOVSLWADEJC-AVGNSLFASA-N 0.000 description 3
ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
102000007327 Protamines Human genes 0.000 description 3
108010007568 Protamines Proteins 0.000 description 3
241000589517 Pseudomonas aeruginosa Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
CDKZJGMPZHPAJC-ULQDDVLXSA-N Tyr-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDKZJGMPZHPAJC-ULQDDVLXSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
108010068380 arginylarginine Proteins 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
229940048914 protamine Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
241000863030 Lysobacter enzymogenes Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
230000000290 insulinogenic effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
241000590035 Achromobacter lyticus Species 0.000 description 1
RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
YNQMEIJEWSHOEO-SRVKXCTJSA-N Asn-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O YNQMEIJEWSHOEO-SRVKXCTJSA-N 0.000 description 1
QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
KOHBWQDSVCARMI-BWBBJGPYSA-N Cys-Cys-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KOHBWQDSVCARMI-BWBBJGPYSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
229920002245 Dextrose equivalent Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010028690 Fish Proteins Proteins 0.000 description 1
QKCZZAZNMMVICF-DCAQKATOSA-N Gln-Leu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O QKCZZAZNMMVICF-DCAQKATOSA-N 0.000 description 1
GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
TWROVBNEHJSXDG-IHRRRGAJSA-N His-Leu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O TWROVBNEHJSXDG-IHRRRGAJSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000007711 Peperomia pellucida Species 0.000 description 1
230000010748 Photoabsorption Effects 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
239000012564 Q sepharose fast flow resin Substances 0.000 description 1
DLPXTCTVNDTYGJ-JBDRJPRFSA-N Ser-Ile-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O DLPXTCTVNDTYGJ-JBDRJPRFSA-N 0.000 description 1
JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
101000759036 Sus scrofa Trypsin Proteins 0.000 description 1
VLDMQVZZWDOKQF-AUTRQRHGSA-N Val-Glu-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VLDMQVZZWDOKQF-AUTRQRHGSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
231100000429 cutaneous necrosis Toxicity 0.000 description 1
238000010612 desalination reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
UVTKHPSJNFFIDG-UHFFFAOYSA-L potassium tetrathionate Chemical compound [K+].[K+].[O-]S(=O)(=O)SSS([O-])(=O)=O UVTKHPSJNFFIDG-UHFFFAOYSA-L 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000012264 purified product Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
108010048818 seryl-histidine Proteins 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000013519 translation Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000001810 trypsinlike Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CN92113309A 1991-11-26 1992-11-25 三精氨酸胰岛素 Pending CN1072723A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80116391A	1991-11-26	1991-11-26
US801,163		1991-11-26

Publications (1)

Publication Number	Publication Date
CN1072723A true CN1072723A (zh)	1993-06-02

Family

ID=25180362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN92113309A Pending CN1072723A (zh)	1991-11-26	1992-11-25	三精氨酸胰岛素

Country Status (17)

Country	Link
US (2)	US5491216A (2)
EP (1)	EP0544466A1 (2)
JP (1)	JP3304442B2 (2)
KR (1)	KR930009591A (2)
CN (1)	CN1072723A (2)
AU (1)	AU2857692A (2)
BR (1)	BR9204542A (2)
CA (1)	CA2083360A1 (2)
CZ (1)	CZ342492A3 (2)
FI (1)	FI925343A7 (2)
HU (2)	HUT63457A (2)
IL (1)	IL103849A0 (2)
MX (1)	MX9206724A (2)
NO (1)	NO924525L (2)
NZ (1)	NZ245170A (2)
TW (1)	TW224471B (2)
ZA (1)	ZA928916B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104017809A (zh) *	2014-06-05	2014-09-03	山东省农业科学院生物技术研究中心	改造的人Insulin蛋白表达基因及表达方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69637130T2 (de) *	1995-02-20	2008-02-21	The Walter And Eliza Hall Institute Of Medical Research, Parkville	Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren
DE59711533D1 (de) *	1996-07-26	2004-05-27	Aventis Pharma Gmbh	Insulinderivate mit erhöhter Zinkbindung
US6444641B1 (en)	1997-10-24	2002-09-03	Eli Lilly Company	Fatty acid-acylated insulin analogs
US6933272B1 (en)	1998-09-22	2005-08-23	Erik Helmerhorst	Use of non-peptidyl compounds for the treatment of insulin related ailments
DK1265630T3 (da)	2000-03-24	2006-10-09	Genentech Inc	Anvendelse af insulin til behandling af brusksygdomme
CZ2004710A3 (cs) *	2001-12-20	2005-02-16	Eli Lilly And Company	Inzulínová sloučenina s protrahovaným účinkem
US20060217290A1 (en) *	2003-04-29	2006-09-28	Kohn Wayne D	Insulin analogs having protracted time action
WO2007081824A2 (en) *	2006-01-06	2007-07-19	Case Western Reserve University	Fibrillation resistant proteins
JP5550338B2 (ja)	2006-07-31	2014-07-16	ノボ・ノルデイスク・エー／エス	ペグ化持続型インスリン
HUE029512T2 (en)	2006-09-22	2017-03-28	Novo Nordisk As	Protease Resistant Insulin Analogs
WO2008043033A2 (en)	2006-10-04	2008-04-10	Case Western Reserve University	Fibrillation-resistant insulin and insulin analogues
JP5496082B2 (ja)	2007-04-30	2014-05-21	ノボ・ノルデイスク・エー／エス	タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2009115469A1 (en)	2008-03-18	2009-09-24	Novo Nordisk A/S	Protease stabilized, acylated insulin analogues
US8993516B2 (en) *	2008-04-14	2015-03-31	Case Western Reserve University	Meal-time insulin analogues of enhanced stability
WO2009132129A2 (en) *	2008-04-22	2009-10-29	Case Western Reserve University	Isoform-specific insulin analogues
KR20120129875A (ko) *	2008-07-31	2012-11-28	케이스 웨스턴 리저브 유니버시티	염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en)	2008-07-31	2015-12-01	Case Western Reserve University	Insulin analogues containing penta-fluoro-Phenylalanine at position B24
US8399407B2 (en) *	2009-09-17	2013-03-19	Case Western Reserve University	Non-standard insulin analogues
JP5866120B2 (ja)	2009-12-11	2016-02-17	ケースウェスタンリザーブユニバーシティＣａｓｅＷｅｓｔｅｒｎｒｅｓｅｒｖｅＵｎｉｖｅｒｓｉｔｙ	塩素化アミノ酸を有するインスリン類似体
CN103533952B (zh) *	2011-03-15	2017-02-15	诺沃—诺迪斯克有限公司	包含半胱氨酸置换的人胰岛素类似物和衍生物
CA2870313A1 (en)	2012-04-11	2013-10-17	Novo Nordisk A/S	Insulin formulations
AU2014333979B2 (en)	2013-10-07	2018-02-15	Novo Nordisk A/S	Novel derivative of an insulin analogue
CA2961037A1 (en)	2014-10-06	2016-04-14	Case Western Reserve University	Biphasic single-chain insulin analogues
WO2016145389A1 (en) *	2015-03-12	2016-09-15	Board Of Trustees Of Michigan State University	Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
EP3341405A4 (en) *	2015-09-24	2019-05-01	Hanmi Pharm. Co., Ltd.	PROCESS FOR INSULIN PRODUCTION
ES2886837T3 (es)	2016-12-16	2021-12-21	Novo Nordisk As	Composiciones farmacéuticas que contienen insulina

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3326473A1 (de) *	1983-07-22	1985-01-31	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) *	1983-07-22	1985-02-14	Hoechst Ag, 6230 Frankfurt	Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
US4569791A (en) *	1984-06-14	1986-02-11	Eli Lilly And Company	Anti-diabetic compounds
US4581165A (en) *	1984-06-14	1986-04-08	Eli Lilly And Company	Anti-diabetic compounds
US4569792A (en) *	1984-06-14	1986-02-11	Eli Lilly And Company	Anti-diabetic compounds
US5008241A (en) *	1985-03-12	1991-04-16	Novo Nordisk A/S	Novel insulin peptides
DK129385A (da) *	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
IL84110A (en) *	1986-10-14	1992-11-15	Lilly Co Eli	Process for transforming a human insulin precursor to a human insulin
US4992418A (en) *	1987-07-17	1991-02-12	Mount Sinai School Of Medicine	Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
DE58906966D1 (de) *	1988-06-23	1994-03-24	Hoechst Ag	Mini-Proinsulin, seine Herstellung und Verwendung.
DE3844211A1 (de) *	1988-12-29	1990-07-05	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) *	1989-03-20	1989-03-20	Nordisk Gentofte	Insulinforbindelser
DE3936876A1 (de) *	1989-11-06	1991-05-23	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5130236A (en) *	1989-12-07	1992-07-14	Eli Lilly And Company	Process for producing des(64,65)-proinsulin
US5139716A (en) *	1990-02-20	1992-08-18	Loral Aerospace Corp.	Method of fabricating coolable ceramic structures

1992
- 1992-11-18 TW TW081109247A patent/TW224471B/zh active
- 1992-11-18 ZA ZA928916A patent/ZA928916B/xx unknown
- 1992-11-18 CZ CS923424A patent/CZ342492A3/cs unknown
- 1992-11-18 NZ NZ24517092A patent/NZ245170A/xx unknown
- 1992-11-19 CA CA002083360A patent/CA2083360A1/en not_active Abandoned
- 1992-11-20 EP EP92310616A patent/EP0544466A1/en not_active Withdrawn
- 1992-11-23 IL IL103849A patent/IL103849A0/xx unknown
- 1992-11-23 MX MX9206724A patent/MX9206724A/es unknown
- 1992-11-24 HU HU9203688A patent/HUT63457A/hu unknown
- 1992-11-24 KR KR1019920022175A patent/KR930009591A/ko not_active Withdrawn
- 1992-11-24 HU HU9203688A patent/HU9203688D0/hu unknown
- 1992-11-24 NO NO92924525A patent/NO924525L/no unknown
- 1992-11-24 AU AU28576/92A patent/AU2857692A/en not_active Abandoned
- 1992-11-25 CN CN92113309A patent/CN1072723A/zh active Pending
- 1992-11-25 JP JP31483692A patent/JP3304442B2/ja not_active Expired - Fee Related
- 1992-11-25 FI FI925343A patent/FI925343A7/fi not_active Application Discontinuation
- 1992-11-25 BR BR9204542A patent/BR9204542A/pt not_active Application Discontinuation
1993
- 1993-07-06 US US08/087,831 patent/US5491216A/en not_active Expired - Fee Related
1995
- 1995-06-06 US US08/466,945 patent/US5698669A/en not_active Expired - Fee Related

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104017809A (zh) *	2014-06-05	2014-09-03	山东省农业科学院生物技术研究中心	改造的人Insulin蛋白表达基因及表达方法

Also Published As

Publication number	Publication date
CA2083360A1 (en)	1993-05-27
MX9206724A (es)	1993-05-01
HU9203688D0 (en)	1993-03-29
FI925343A0 (fi)	1992-11-25
JP3304442B2 (ja)	2002-07-22
NO924525L (no)	1993-05-27
FI925343L (fi)	1993-05-27
HUT63457A (en)	1993-08-30
NZ245170A (en)	1994-07-26
JPH05286998A (ja)	1993-11-02
US5491216A (en)	1996-02-13
CZ342492A3 (en)	1993-06-16
BR9204542A (pt)	1993-06-01
ZA928916B (en)	1994-05-18
AU2857692A (en)	1993-05-27
NO924525D0 (no)	1992-11-24
KR930009591A (ko)	1993-06-21
TW224471B (2)	1994-06-01
IL103849A0 (en)	1993-04-04
US5698669A (en)	1997-12-16
FI925343A7 (fi)	1993-05-27
EP0544466A1 (en)	1993-06-02

Legal Events

Date	Code	Title
1993-06-02	C06	Publication
1993-06-02	PB01	Publication
1995-11-08	C01	Deemed withdrawal of patent application (patent law 1993)
1995-11-08	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CN1483831A (zh)	2004-03-24	获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法
CN1229388C (zh)	2005-11-30	N－端化学修饰的蛋白质组合物及方法
CN1300220A (zh)	2001-06-20	肽组合物和制剂及其使用
CN1468258A (zh)	2004-01-14	胰高血糖素样肽-1类似物
CN1362968A (zh)	2002-08-07	新的肽
CN1188485A (zh)	1998-07-22	胰高血糖素样肽-2及其治疗应用
CN1037711A (zh)	1989-12-06	具有t细胞辅助活性的肽类
CN1129224A (zh)	1996-08-21	类胰高血糖素促胰岛素的多肽类似物组合物及其使用方法
CN1157408C (zh)	2004-07-14	以糖蛋白激素四成员家族的单链形式存在的糖蛋白激素活性的促效剂或拮抗剂
CN1045793A (zh)	1990-10-03	新的胰岛素化合物及其制备方法
CA2083360A1 (en)	1993-05-27	Tri-arginine insulins
CN1255945A (zh)	2000-06-07	利用辅助肽制造肽的方法
CN1422278A (zh)	2003-06-04	kahalalide F及相关化合物
CN1398897A (zh)	2003-02-26	一组合成抗菌肽
CN1061606A (zh)	1992-06-03	具有生长激素释放活性的多肽化合物
CN1304450A (zh)	2001-07-18	具有增强的锌结合力的新型胰岛素类似物
CN1917898A (zh)	2007-02-21	用于治疗非典型肺部感染的血管活性肠肽的生物活性物质
CN1612748A (zh)	2005-05-04	用于眼睛干燥及与眼睛干燥相关的疾病的治疗剂
CN1231259C (zh)	2005-12-14	生产人胰岛素
CN1291199A (zh)	2001-04-11	含有分子内伴侣样序列的嵌合蛋白及其在胰岛素生产中的应用
CN1330665A (zh)	2002-01-09	多结构域糖蛋白激素及其使用方法
CN1597697A (zh)	2005-03-23	一种人的甲状旁腺素1－34肽相关肽－Pro－Pro－[Arg11]]hPTH(1－34)－Pro－Pro
CN1119650A (zh)	1996-04-03	具有胃肠道运动刺激活性的胃动素样多肽
CN1190437A (zh)	1998-08-12	骨刺激因子
CN1950394A (zh)	2007-04-18	在受试者中抑制免疫复合物形成的方法

CN1072723A - 三精氨酸胰岛素 - Google Patents

Info

Links

Images

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=25180362

Family Applications (1)

Country Status (17)

Cited By (1)

Families Citing this family (26)

Family Cites Families (15)

Cited By (1)

Also Published As

Similar Documents

Legal Events